GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

APYX · Sep 30, 2024

Apyx Medical Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-24-034193General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

326.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity50thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.33% · OPTIONAL · VALID

Operating cash generation38thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-38.65% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-4.08% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure38thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

78.35% · OPTIONAL · VALID

Gross margin13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

60.54% · CORE · VALID

Operating margin88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-31.64% · CORE · VALID

R&D intensity38thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

9.94% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

8.68% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/9 normalizedLevel 3Dec 31, 20247/9 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
2.38%
Current
1.33%
Delta
-1.05%
Cash Generation Decreased
Previous
-35.63%
Current
-38.65%
Delta
-3.02%
Growth Increased
Previous
-10.46%
Current
-4.08%
Delta
6.38%
Inventory Pressure Increased
Previous
76.75%
Current
78.35%
Delta
1.60%
Margin Decreased
Previous
61.68%
Current
60.54%
Delta
-1.14%
Profitability Increased
Previous
-45.66%
Current
-31.64%
Delta
14.01%
R And D Intensity Decreased
Previous
11.72%
Current
9.94%
Delta
-1.78%
Sbc Intensity Increased
Previous
8.64%
Current
8.68%
Delta
0.04%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · APYX Fundamental State →Transitioned To · APYX SBC_INTENSITY_INCREASED →Transitioned To · APYX Fundamental State →Transitioned To · APYX CAPEX_INTENSITY_DECREASED →Transitioned To · APYX CASH_GENERATION_DECREASED →Transitioned To · APYX GROWTH_INCREASED →Transitioned To · APYX INVENTORY_PRESSURE_INCREASED →Transitioned To · APYX MARGIN_DECREASED →Transitioned To · APYX PROFITABILITY_INCREASED →Transitioned To · APYX R_AND_D_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.